文献速递胸部肿瘤放疗放疗物理与技术

胸部放疗联合抗PD-1抗体降低生存并与心脏及肺组织T细胞浸润增加相关

Decreased Survival After Combining Thoracic Irradiation and an Anti-PD-1 Antibody Correlated With Increased T-cell Infiltration Into Cardiac and Lung Tissues.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-06-26

该临床前小鼠研究将6–8周龄C57Bl/6小鼠随机接受抗PD-1抗体或对照IgG联合或不联合胸部放疗(20Gy),以生存为终点。放疗后21天,IgG+放疗组生存率70%,显著高于抗PD-1+放疗组的36%(p=0.0169);流式细胞术与组织学均显示联合治疗组心脏和肺组织T细胞计数显著升高。结论提示照射损伤的正常组织更易受活化T细胞进一步损伤。

要点

  • 胸部放疗(20Gy)联合抗PD-1抗体较单用放疗显著降低小鼠21天生存率。
  • 联合治疗组心脏和肺组织T细胞计数较单药或单放疗组显著升高。
  • 照射损伤的正常组织可能更易被活化T细胞进一步损伤。

核心结论

  • 抗PD-1抗体联合胸部照射导致小鼠肺和心脏组织T细胞浸润并增加死亡率。
  • 照射损伤的健康组织更易受到活化T细胞的进一步损伤。

研究设计与样本

  • 临床前小鼠研究,使用6–8周龄C57Bl/6小鼠。
  • 分组接受抗PD-1抗体或对照IgG,联合或不联合胸部放疗(20Gy)。
  • 以生存为终点监测毒性,并用流式细胞术和组织学分析心脏与肺组织免疫细胞浸润。

主要发现

  • 放疗后21天,IgG+放疗组生存率70%,显著高于抗PD-1+放疗组的36%(p=0.0169)。
  • 流式细胞术显示联合治疗组心脏T细胞计数显著高于单用抗PD-1抗体组(6.1 vs 22.4,p<0.001)和IgG+放疗组(11.3 vs 22.4,p<0.05)。
  • 流式细胞术显示联合治疗组肺T细胞计数显著高于单用抗PD-1抗体组(3.4 vs 20.8,p<0.001)和IgG+放疗组(12.2 vs 20.8,p<0.05)。
  • 组织学分析证实联合治疗组心脏T细胞计数显著高于单用抗PD-1抗体组(464 vs 679 cells per field,p<0.001)和IgG+放疗组(526 vs 679 cells per field,p<0.001)。
  • 组织学分析证实联合治疗组肺T细胞计数显著高于单用抗PD-1抗体组(780 vs 1109,p<0.001)和IgG+放疗组(848 vs 1109,p<0.05)。

临床怎么用

  • 在临床前模型中,胸部放疗联合抗PD-1抗体可能增加心脏和肺组织的T细胞浸润及毒性风险。
  • 提示临床联合治疗时需关注正常心肺组织的免疫相关损伤,但需进一步临床研究验证。

局限性

  • 研究为临床前小鼠模型,结果不能直接外推至人类。
  • 样本量、具体随机方法及盲法等信息原文未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Lung cancer is the leading cause of cancer-related mortality in the United States. Radiation, a common component of treatment, can cause acute damage to critical organs including the lungs and the heart, but the serious toxicities from radiotherapy alone is relatively rare. A recent addition to the treatment regimen is immunotherapy, such as anti-PD-1 antibody, which blocks the inhibition of activated T cells. Combining anti-PD-1 treatment and thoracic radiation has potential for improving the outcomes of locally advanced lung cancer over traditional chemoradiation regimens, but the effect of combining these therapies on non-malignant lung tissue has not yet been investigated in preclinical models. MATERIALS AND METHODS: 6–8 week old C57Bl/6 mice were treated with either anti-PD-1 antibody or control IgG with or without thoracic radiation (20Gy), and survival was monitored as an end point to determine any potential increase of toxicity from the combination therapy. Immune cell infiltration into the irradiated cardiac and lung tissues was analyzed via flow cytometry and histologically. RESULTS: At 21 days post-radiation, 70% of animals in the IgG + radiation group survived, significantly more than the anti-PD-1 + radiation group (36%; p=0.0169). T cell counts were significantly elevated in both cardiac and pulmonary tissues after combination therapy as compared to anti-PD-1 antibody alone (heart: 6.1 vs 22.4, p<0.001; lung 3.4 vs 20.8, p<0.001) or control IgG plus radiation (heart 11.3 vs 22.4, p<0.05; lung 12.2 vs 20.8, p<0.05) in flow cytometric studies. Histologic analysis confirmed this increase in the comparison of anti-PD-1 antibody alone versus antibody plus irradiation (heart: 464 vs 679 cells per field, p<0.001; lung: 780 vs 1109, p<0.001) and control IgG plus radiation or combination therapy (heart: 526 vs 679 cells per field, p<0.001; lung: 848 vs 1109, p<0.05). CONCLUSIONS: Combining anti-PD-1 antibody and thoracic irradiation results in T cell infiltration into lung and heart tissue and increases mortality in a preclinical model. We conclude that healthy tissue damaged by irradiation is more susceptible to further damage by activated T cells.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Myers CJ, Lu B. Decreased Survival After Combining Thoracic Irradiation and an Anti-PD-1 Antibody Correlated With Increased T-cell Infiltration Into Cardiac and Lung Tissues. Int J Radiat Oncol Biol Phys. 2017. PMID: 29165283. doi:10.1016/j.ijrobp.2017.06.2452

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。